Volume 23 Issue 1
Jan.  2025
Turn off MathJax
Article Contents
Article Navigation >  Chinese Journal of General Practice  > 2025  >  23(1): 17-20
ZHANG Qun, ZHOU Shixiang, SHI Xueling, YU Dingyue, ZHOU Ying, YU Jiaqi, LI Duojie. Analysis of the efficacy of combined immunotherapy and radiotherapy in patients with brain metastasis from driver-gene negative non-small cell lung cancer[J]. Chinese Journal of General Practice, 2025, 23(1): 17-20. doi: 10.16766/j.cnki.issn.1674-4152.003826
Citation: ZHANG Qun, ZHOU Shixiang, SHI Xueling, YU Dingyue, ZHOU Ying, YU Jiaqi, LI Duojie. Analysis of the efficacy of combined immunotherapy and radiotherapy in patients with brain metastasis from driver-gene negative non-small cell lung cancer[J]. Chinese Journal of General Practice, 2025, 23(1): 17-20. doi: 10.16766/j.cnki.issn.1674-4152.003826
shu

Analysis of the efficacy of combined immunotherapy and radiotherapy in patients with brain metastasis from driver-gene negative non-small cell lung cancer

doi: 10.16766/j.cnki.issn.1674-4152.003826

  • Department of Radiotherapy, the First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui 233004, China

Funds:

 2022AH051511

 2021byzd173

  • Received Date: 2024-06-01
    Available Online: 2025-02-13
    Abstract
  •   Objective  Exploring the efficacy and safety of combined immunotherapy and radiotherapy in patients with brain metastasis from driver-gene negative non-small cell lung cancer (NSCLC).  Methods  A total of 108 NSCLC patients with brain metastasis, admitted to the First Affiliated Hospital of Bengbu Medical University from January 2020 to December 2023, were selected as the research objects. Patients were divided into the cranial radiotherapy group (single group, 60 cases) and the combined immunotherapy plus cranial radiotherapy group (combined group, 48 cases) according to treatment Methods. The efficacy and toxicity of the two groups were compared. In addition, patients in the combined therapy group were further subdivided into three subgroups: group A (whole brain radiotherapy, WBRT), group B (WBRT combined with local dose radiotherapy), and group C (local radiotherapy) according to the different modes of cranial radiotherapy. The treatment outcomes and side effects of the different radiotherapy modes were compared among the subgroups.  Results  The intracranial Objective response rate (iORR) and disease control rate (iDCR) in the combined therapy group were higher than those of the single therapy group [54.17% (26/48) vs. 35.00% (21/60), χ2=3.985, P=0.046; 75.00% (36/48) vs. 56.67% (34/60), χ2=3.930, P=0.047]. Both groups had tolerable adverse reactions. The comparison of intracranial efficacy among the three subgroups in the combined therapy group showed that the iORR and iDCR of group B were higher than those in the group A (P < 0.001), with no significant difference in the incidence of side effects among the three groups (P>0.05).  Conclusion  Immunotherapy combined with radiotherapy is effective in patients with brain metastasis from driver gene-negative NSCLC. This combination improves the disease control rate without significantly increasing side effects.

     

    • FullText(HTML)
  • loading
    • References(21)
  • [1]
    SIEGEL R L, GIAQUINTO A N, JEMAL A. Cancer statistics, 2024[J]. CA Cancer J Clin, 2024, 74(1): 12-49. doi: 10.3322/caac.21820
    [2]
    郑荣寿, 陈茹, 韩冰峰, 等. 2022年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂志, 2024, 46(3): 221-231. doi: 10.3760/cma.j.cn112152-20240119-00035

    ZHENG R S, CHEN R, HAN B F, et al. Prevalence of malignant tumors in China in 2022[J]. Chinese Journal of Oncology, 2024, 46(3): 221-231. doi: 10.3760/cma.j.cn112152-20240119-00035
    [3]
    LAMBA N, KEARNEY R B, CATALANO P J, et al. Population-based estimates of survival among elderly patients with brain metastases[J]. Neuro Oncol, 2021, 23(4): 661-676. doi: 10.1093/neuonc/noaa233
    [4]
    HENDRIKS L E, KERR K M, MENIS J, et al. Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up[J]. Ann Oncol, 2023, 34(4): 339-357. doi: 10.1016/j.annonc.2022.12.009
    [5]
    HENDRIKS L E, KERR K M, MENIS J, et al. Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up[J]. Ann Oncol, 2023, 34(4): 358-376. doi: 10.1016/j.annonc.2022.12.013
    [6]
    ALTAN M, WANG Y, SONG J, et al. Nivolumab and ipilimumab with concurrent stereotactic radiosurgery for intracranial metastases from non-small cell lung cancer: analysis of the safety cohort for non-randomized, open-label, phase Ⅰ/Ⅱ trial[J]. J Immunother Cancer, 2023, 11(7): e6871. DOI: 10.1136/jitc-2023-006871.
    [7]
    陈旭澜, 李泞甫, 肖剑波, 等. 非小细胞肺癌脑转移的免疫治疗现状及进展[J]. 中国临床研究, 2023, 36(6): 821-826.

    CHEN X L, LI N F, XIAO J B, et al. Current status and progress of immunotherapy for brain metastases in non-small cell lung cancer[J]. Chinese Journal of Clinical Research, 2023, 36(6): 821-826.
    [8]
    孙逸初, 梁飞, 夏铀铀. 非小细胞肺癌脑转移放疗联合免疫治疗的研究进展[J]. 肿瘤防治研究, 2023, 50(7): 705-709. doi: 10.3971/j.issn.1000-8578.2023.22.1322

    SUN Y C, LIANG F, XIA Y Y. Research progress on brain metastases combined with radiotherapy combined with immunotherapy for brain metastases in non-small cell lung cancer[J]. Cancer Prevention and Treatment Research, 2023, 50(7): 705-709. doi: 10.3971/j.issn.1000-8578.2023.22.1322
    [9]
    CASTELLANI G, CROESE T, PERALTA RAMOS J M, et al. Transforming the understanding of brain immunity[J]. Science, 2023, 380(6640): eabo7649. DOI: 10.1126/science.abo7649.
    [10]
    LI M, HOU X, SAI K, et al. Immune suppressive microenvironment in brain metastatic non-small cell lung cancer: comprehensive immune microenvironment profiling of brain metastases versus paired primary lung tumors (GASTO 1060)[J]. OncoImmunology, 2022, 11(1): 2059874. DOI: 10.1080/2162402X.2022.2059874.
    [11]
    WANG Y, WANG L, LI T, et al. Bimetallic nanoparticles as cascade sensitizing amplifiers for low-dose and robust cancer radio-immunotherapy[J]. Acta pharmaceutica Sinica. B, 2024, 14(4): 1787-1800. doi: 10.1016/j.apsb.2023.11.028
    [12]
    MANSFIELD A S, HERBST R S, DE CASTRO G J, et al. Outcomes with pembrolizumab monotherapy in patients with programmed death-ligand 1-positive NSCLC with brain metastases: pooled analysis of KEYNOTE-001, 010, 024, and 042[J]. JTO Clin Res Rep, 2021, 2(8): 100205. DOI: 10.1016/j.jtocrr.2021.100205.
    [13]
    郑晓丽, 王晓辉, 孙亚楠, 等. 非小细胞肺癌脑转移一线免疫联合放疗疗效分析[J]. 中华放射肿瘤学杂志, 2023, 32(12): 1044-1050. doi: 10.3760/cma.j.cn113030-20221009-00333

    ZHEGN X L, WANG X H, SUN Y N, et al. Efficacy of first-line immunotherapy combined with radiotherapy for brain metastases in non-small cell lung cancer[J]. Chinese Journal of Radiation Oncology, 2023, 32(12): 1044-1050. doi: 10.3760/cma.j.cn113030-20221009-00333
    [14]
    ABDULHALEEM M, JOHNSTON H, D' AGOSTINO R J R, et al. Local control outcomes for combination of stereotactic radiosurgery and immunotherapy for non-small cell lung cancer brain metastases[J]. J Neurooncol, 2022, 157(1): 101-107. doi: 10.1007/s11060-022-03951-7
    [15]
    PORTE J, SAINT-MARTIM C, FREDERIC-MOREAU T, et al. Efficacy and safety of combined brain stereotactic radiotherapy and immune checkpoint inhibitors in non-small-cell lung cancer with brain metastases[J]. Biomedicines, 2022, 10(9): 2249. DOI: 10.3390/biomedicines10092249.
    [16]
    VELLAYAPPAN B A, MCGRANAHAN T, GRABER J, et al. Radiation necrosis from stereotactic radiosurgery: How do we mitigate?[J]. Curr Treat Options Oncol, 2021, 22(7): 57. DOI: 10.1007/s11864-021-00854-z.
    [17]
    LEHRER E J, AHUWALIA M S, GUREWITZ J, et al. Imaging-defined necrosis after treatment with single-fraction stereotactic radiosurgery and immune checkpoint inhibitors and its potential association with improved outcomes in patients with brain metastases: an international multicenter study of 697 patients[J]. J Neurosurg, 2022, 138(5): 1178-1187.
    [18]
    ZHU K K, WEI J L, XU Y H, et al. Effect of stereotactic body radiation therapy on diverse organ lesions in advanced non-small cell lung cancer patients receiving immune checkpoint inhibitors[J]. Curr Med Sci, 2023, 43(2): 344-359. doi: 10.1007/s11596-023-2702-0
    [19]
    董晶. 肺癌脑转移患者全脑放疗后认知功能状况的研究[J]. 中华放射肿瘤学杂志, 2023, 32(10): 900-906. doi: 10.3760/cma.j.cn113030-20230203-00020

    DONG J. Study on cognitive function of patients with brain metastases of lung cancer after whole-brain radiotherapy[J]. Chinese Journal of Radiation Oncology, 2023, 32(10): 900-906. doi: 10.3760/cma.j.cn113030-20230203-00020
    [20]
    赵皓, 齐学远, 王俊斌, 等. 外周血淋巴细胞亚群在非小细胞肺癌中的表达及意义[J]. 中华全科医学, 2023, 21(11): 1849-1851.

    ZHAO H, QI X Y, WANG J B, et al. Expression and significance of peripheral blood lymphocyte subsets in non-small cell lung cancer[J]. Chinese Journal of General Practice, 2023, 21(11): 1849-1851.
    [21]
    王朝, 韩雪, 张爱霞. LIPI评分对PD-1/PD-L1抑制剂治疗非小细胞肺癌效果与预后的价值分析[J]. 中国现代医学杂志, 2023, 33(6): 55-60.

    WANG C, HAN X, ZHAGN A X. Value analysis of LIPI score on the efficacy and prognosis of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer[J]. Chinese Journal of Modern Medicine, 2023, 33(6): 55-60.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)  / Tables(5)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (39) PDF downloads(2) Cited by()
    Proportional views
    Related

    Address：No. 287, Changhuai Road, Bengbu, Anhui Province, 233004, P.R.ChinaphoneNo：0552-3066635； 0552-3051890Email：zhqkyx@163.com

    Copyright © Chinese Journal of General Practice皖ICP备2020018345号-2

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return